Thailand market access secured for full orthopaedic product range
Osteopore Limited (ASX: OSX) has secured market access in Thailand for its full range of orthopaedic products, including its flagship product for medial opening wedge high tibial osteotomy procedures. The announcement marks a concrete step in the company’s ASEAN regional expansion, moving beyond market evaluation into active commercial execution.
Underpinning the market entry is a partnership with DCH Auriga (Auriga), an Asia-based integrated market management provider specialising in healthcare. Under the arrangement, Auriga will serve as Osteopore’s market authorisation holder, importing the company’s regenerative devices into Thailand and supplying hospitals and clinics as directed by Osteopore.
When big ASX news breaks, our subscribers know first
A fast-growing market with clear addressable opportunity
Thailand’s orthopaedic devices market was valued at approximately USD 749 million in 2025 and is projected to reach approximately USD 1.5 billion by 2033, according to Datacube Research. That trajectory reflects a compound annual growth rate (CAGR) of 9.2%, placing it among the fastest-growing orthopaedic markets in the Asia-Pacific region.
Osteopore’s products sit within the bone-repair orthobiologics and bone graft substitutes segment, which typically accounts for approximately 8–10% of the total orthopaedic devices market by value. On that basis, the company estimates its addressable segment in Thailand at approximately USD 60–80 million annually.
| Market | 2025 Value (USD) | 2033 Projection (USD) | CAGR |
|---|---|---|---|
| Thailand orthopaedic devices (total) | ~$749 million | ~$1.5 billion | 9.2% |
| Bone-repair orthobiologics segment (est.) | ~$60–80 million (annual) | — | — |
Source: Datacube Research, Thailand Orthopedic Devices Market, 2025; segment estimate by Osteopore.
Several structural factors are expected to sustain demand within this segment:
- Universal healthcare coverage expanding access to reconstructive procedures
- A rising orthopaedic disease burden across the population
- One of the world’s highest road-trauma rates, generating sustained demand for bone defect reconstruction materials
How Osteopore’s technology addresses the opportunity
Osteopore’s products are 3D-printed scaffolds designed to support the body’s natural bone regeneration process. The scaffolds are biomimetic, meaning they are structured to closely resemble natural bone, and bioresorbable, meaning the material gradually dissolves within the body over time.
As the scaffold dissolves, it is replaced by healthy bone tissue grown by the patient’s own body. This approach is intended to reduce the post-surgery complications often associated with permanent bone implants, which remain in the body indefinitely.
The clinical rationale for bioresorbable scaffolds is particularly compelling in paediatric and younger patients, as illustrated by the Hainan case where a bioresorbable scaffold chosen over a permanent implant avoided the multiple revision surgeries a permanent device would have required over the patient’s lifetime.
In the Thai context, this technology is well-suited to the demand drivers already identified. Trauma from high-energy road accidents frequently leaves patients with significant bone defects requiring reconstruction, and bioresorbable scaffolds offer a solution that supports healing without leaving a permanent foreign object in the body. Similarly, patients accessing reconstructive procedures under Thailand’s universal healthcare coverage may benefit from a material that simplifies long-term post-operative management.
DCH Auriga partnership and the path to hospital listings
Auriga’s role in the arrangement is precisely defined: it will act as market authorisation holder, importing Osteopore’s regenerative devices into Thailand and distributing them to hospitals and clinics as directed by Osteopore. This structure gives Osteopore directional control over where its products are placed while leveraging Auriga’s established in-country infrastructure.
Auriga brings considerable regional reach to the partnership. The company has operated across Asia for over 50 years, distributes more than 500 brands across over 10,000 points of sale, and maintains operations in Hong Kong, Macau, mainland China, Singapore, Thailand, Indonesia, Brunei, Malaysia, Vietnam and the Philippines.
The immediate next step following market access approval is product listing in target public and private hospitals in Bangkok.
The immediate next step following market access approval is product listing in target public and private hospitals in Bangkok, a process that mirrors the pathway Osteopore followed after its neurosurgery approval at Thammasat University Hospital, where product listing at a major academic referral centre preceded broader clinical adoption.
Dr Yujing Lim, CEO, Osteopore Limited
“Our team has evaluated the potential of regional markets and Thailand has been identified as one of our key markets in ASEAN. I am glad to see that the team is smoothly executing on our regional expansion plans.
“We have also had the opportunity to share more about our regenerative devices in various meetings and conferences, and are looking forward to formal engagements.”
With market authorisation secured and a distribution partner in place, formal hospital engagements in Bangkok represent the next commercial milestone. The announcement does not disclose specific revenue targets or timelines for product listings.
Don’t Miss the Next Healthcare Breakout
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ investors already staying ahead of the market. Click the “Free Alerts” button at StockWire X to get the next market-moving announcement the moment it drops.